Ehrenstein Lab UCL

A Rheumatology Lab with a passion for Arthritis, Systemic Lupus and Experimental Research🔬👩‍🔬👨‍🔬

[Michael Ehrenstein @MikeEhrenstein]

Very proud of @MuhammadShipa who successfully defended his thesis this afternoon. Well done! Thanks to @VersusArthritis and @LUPUSUK for supporting his research.

[Paul Howard 🐈🐈‍⬛ @PaulAHoward89]

An excellent talk by @MikeEhrenstein about new treatments and approaches to target B cells and BAFF in #lupus.
#BSR23

[Ehrenstein Lab UCL @EhrensteinLab]

@McDonnellLab Well-deserved Thomas!! Congratulations! 🥳

[Ehrenstein Lab UCL @EhrensteinLab]

Well done to @MuhammadShipa on your talk at the #BSR23 on #biomarkers of response to belimumab and rituximab combination - results from the BEAT-LUPUS #SLE trial

[Michael Ehrenstein @MikeEhrenstein]

Could a simple blood test, IgA2 anti-dsDNA antibodies, identify #lupus patients who will respond to #belimumab after #rituximab therapy? Biomarker analyses of the BEAT-lupus trial. @MuhammadShipa @Liliana57970549 @VersusArthritis @GSK @UCLHresearch
https://t.co/Rt3epgYek0

[Ehrenstein Lab UCL @EhrensteinLab]

A lovely day spent at the UCLH Rheumatology Research Open Day organised by @UCLHRheumPPI with patient partners learning about the research questions which are important to them. Grateful for the opportunity to share our research today! @MuhammadShipa @SuAnnYeoh1

[Ehrenstein Lab UCL @EhrensteinLab]

@pedrommcmachado @ucl Congratulations, Professor Machado!

[Ehrenstein Lab UCL @EhrensteinLab]

Well done to @MuhammadShipa from the @EhrensteinLab for his interesting lab data from the Beat Lupus #sle trial at the @ucl Division of Medicine Research Retreat today #LUPUS

[Ehrenstein Lab UCL @EhrensteinLab]

#EULAR2022 #EULAR22 #EULAR #SLE

[Ehrenstein Lab UCL @EhrensteinLab]

So very proud of @MuhammadShipa presenting his talk on IgA2 anti-DNA autoantibodies as a biomarker in SLE of response to belimumab after rituximab and of active renal disease @eular_org @MikeEhrenstein

[Antony Psarras @AntonyPsarras]

SLE pathogenesis: @MuhammadShipa from @EhrensteinLab shows that high levels of serum IgA2 anti-dsDNA antibodies can predict response to #belimumab after rituximab in #lupus patients, but high serum IL-6 levels is a negative predictor of response. #EULAR2022 #RheumTwitter #SLE

[Michael Ehrenstein @MikeEhrenstein]

Very proud of my two clinical fellows who are giving talks at #EULAR2022. @yeoh_su tomorrow at 4.30 about #rheumatoid arthritis and @MuhammadShipa on #lupus and biomarkers from the BEAT-lupus trial on Friday at 10.30.

[Ehrenstein Lab UCL @EhrensteinLab]

Congratulations to @MuhammadShipa for receiving the Annals of Internal Medicine Junior Investigator Award for his publication of the BEAT-LUPUS RCT data, “Effectiveness of belimumab after rituximab in SLE” https://t.co/ZooJ4yzkJ4 @MikeEhrenstein

[DoM_UCL @DoM_UCL]

Congratulations to @MuhammadShipa for receiving his Junior Investigator Award👏 @uclmedsci @domearlycareers
https://t.co/oSKn7nob4f

[Michael Ehrenstein @MikeEhrenstein]

Well done @MuhammadShipa, this is for BEAT-lupus so thanks again to the whole team who were involved..see https://t.co/xDDXahnnxB data from the trial to be presented at #EULAR2022 in the #Lupus oral abstract session on Friday

[Annals of Int Med @AnnalsofIM]

New this week: An #RCT from @MikeEhrenstein @uclnews suggests that a new drug treatment pattern reduced disease symptoms by 3x for patients with persistent, acute #lupus. @EhrensteinLab https://t.co/wnUNFOSjin

[Michael Ehrenstein @MikeEhrenstein]

A must read for anyone planning an RCT in #lupus in UK!

[Ehrenstein Lab UCL @EhrensteinLab]

This would not have been possible without patients, great collaboration from clinical investigators from individual sites and funders - A heartfelt thank you! @VersusArthritis @UCLHresearch @GSK @ucl @LUPUSUK @RheumTrialsUCL @UCLHRheumPPI

[Ehrenstein Lab UCL @EhrensteinLab]

Our publication of the BEAT-LUPUS RCT (Effectiveness of Belimumab After Rituximab in SLE) is finally out! 🎉 Congratulations to the BEAT-LUPUS team of researchers & investigators @MuhammadShipa @MarieaParvaz @Liliana57970549 @MikeEhrenstein @CarolinendLupus @UCL_CCTU

[Ehrenstein Lab UCL @EhrensteinLab]

Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus: A Randomized Controlled Trial: Annals of Internal Medicine: Vol 0, No 0 https://t.co/g6taArcxSL

[Michael Ehrenstein @MikeEhrenstein]

Its taken 8 years to publication today! Thanks to the colleagues, funders and patients who made this possible. 3fold fewer #lupus flares with belimumab after Rituximab @VersusArthritis⁩ ⁦@UCLHresearch⁩ ⁦@GSK⁩ ⁦@ucl⁩ ⁦@LUPUSUK⁩ https://t.co/hMCMHTSeah

[muhammad shipa @MuhammadShipa]

Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus: A Randomized Controlled Trial: Annals of Internal Medicine: Vol 0, No 0 https://t.co/MWqmAROJeu